Keros Therapeutics (KROS) Retained Earnings: 2019-2025
Historic Retained Earnings for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to -$458.3 million.
- Keros Therapeutics' Retained Earnings rose 12.33% to -$458.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$458.3 million, marking a year-over-year increase of 12.33%. This contributed to the annual value of -$568.8 million for FY2024, which is 49.12% down from last year.
- Per Keros Therapeutics' latest filing, its Retained Earnings stood at -$458.3 million for Q3 2025, which was down 1.61% from -$451.0 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Retained Earnings registered a high of -$80.9 million during Q1 2021, and its lowest value of -$568.8 million during Q4 2024.
- Moreover, its 3-year median value for Retained Earnings was -$424.5 million (2024), whereas its average is -$418.6 million.
- In the last 5 years, Keros Therapeutics' Retained Earnings slumped by 156.47% in 2021 and then rose by 12.33% in 2025.
- Over the past 5 years, Keros Therapeutics' Retained Earnings (Quarterly) stood at -$123.8 million in 2021, then tumbled by 84.59% to -$228.4 million in 2022, then slumped by 66.97% to -$381.4 million in 2023, then plummeted by 49.12% to -$568.8 million in 2024, then rose by 12.33% to -$458.3 million in 2025.
- Its last three reported values are -$458.3 million in Q3 2025, -$451.0 million for Q2 2025, and -$420.3 million during Q1 2025.